CA2253943A1 - Treatment of asthma and airway diseases - Google Patents

Treatment of asthma and airway diseases

Info

Publication number
CA2253943A1
CA2253943A1 CA002253943A CA2253943A CA2253943A1 CA 2253943 A1 CA2253943 A1 CA 2253943A1 CA 002253943 A CA002253943 A CA 002253943A CA 2253943 A CA2253943 A CA 2253943A CA 2253943 A1 CA2253943 A1 CA 2253943A1
Authority
CA
Canada
Prior art keywords
treatment
asthma
airway diseases
relates
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002253943A
Other languages
French (fr)
Other versions
CA2253943C (en
Inventor
Alastair George Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL IP Investments Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9766A external-priority patent/AUPN976696A0/en
Priority claimed from AUPN9918A external-priority patent/AUPN991896A0/en
Application filed by Individual filed Critical Individual
Publication of CA2253943A1 publication Critical patent/CA2253943A1/en
Application granted granted Critical
Publication of CA2253943C publication Critical patent/CA2253943C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Abstract

The invention relates to use of steroids or steroid analogues in the treatment of chronic and acute inflammation of the airways, particularly asthmatic conditions. It also relates to compounds and compositions which modulate airway remodelling. In a preferred embodiment, the steroid is 2-methoxyoestradiol.
CA002253943A 1996-05-09 1997-05-09 Treatment of asthma and airway diseases Expired - Fee Related CA2253943C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPN9766A AUPN976696A0 (en) 1996-05-09 1996-05-09 Treatment of asthma and airway diseases
AUPN9766 1996-05-09
AUPN9918 1996-05-20
AUPN9918A AUPN991896A0 (en) 1996-05-20 1996-05-20 Treatment of asthma and airway diseases
PCT/AU1997/000286 WO1997042958A1 (en) 1996-05-09 1997-05-09 Treatment of asthma and airway diseases

Publications (2)

Publication Number Publication Date
CA2253943A1 true CA2253943A1 (en) 1997-11-20
CA2253943C CA2253943C (en) 2009-09-29

Family

ID=25645169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253943A Expired - Fee Related CA2253943C (en) 1996-05-09 1997-05-09 Treatment of asthma and airway diseases

Country Status (8)

Country Link
US (2) US5962445A (en)
EP (1) EP0923376B1 (en)
JP (1) JP4228116B2 (en)
CN (1) CN1245982C (en)
AT (1) ATE281170T1 (en)
CA (1) CA2253943C (en)
DE (1) DE69731473T2 (en)
WO (1) WO1997042958A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
CA2339835C (en) 1998-08-11 2008-12-16 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
WO2003063791A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
CN102727501A (en) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 Uses of sapogenins and their derivatives
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
EP1610798A4 (en) * 2003-02-20 2007-08-08 Univ Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
WO2004101595A1 (en) * 2003-05-13 2004-11-25 Cryptopharma Pty Ltd Estratriene derivatives
JP2006526025A (en) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド Anti-angiogenic agent
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
JP2007529426A (en) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド Anti-angiogenic drugs
CA2580264A1 (en) * 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
CA2587448A1 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
US20070048230A1 (en) * 2005-08-24 2007-03-01 Walter Parsadayan Pheromone compositions and methods
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
WO2007109312A2 (en) 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20080234243A1 (en) * 2007-01-31 2008-09-25 Lavallee Theresa M Method of treating amyloidosis mediated diseases
EP2117529A4 (en) * 2007-02-06 2010-07-28 Res Foundation Of The State Un Methods for treating diseases of altered ige regulation
HUE055562T2 (en) 2011-11-23 2021-11-29 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN102793689A (en) * 2012-09-12 2012-11-28 郑州大学 2-methoxyestradiol dry powder inhalant serving as antitumor medicament and preparation method thereof
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (en) 2016-04-01 2019-01-29 Therapeuticsmd Inc pharmaceutical composition of steroid hormone
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
PL244930B1 (en) * 2021-12-08 2024-04-02 Gdanski Univ Medyczny Use of 2-methoxyestradiol in the treatment of mastocytosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274056A (en) * 1963-05-17 1966-09-20 American Cyanamid Co Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate
US4427669A (en) * 1982-06-28 1984-01-24 The Board Of Regents Of The University Of Nebraska Contraceptive
US4420428A (en) * 1982-12-27 1983-12-13 E. R. Squibb & Sons, Inc. 16-Ketoandrostene-17-dithioketals
DE3344834A1 (en) * 1983-12-08 1985-06-13 Schering AG, 1000 Berlin und 4709 Bergkamen NEW HYDROCORTISON AND PREDNISOLON DERIVATIVES
US4529548A (en) * 1984-05-07 1985-07-16 E. R. Squibb & Sons, Inc. 17β-(substituted thio)androstenes
US4529547A (en) * 1984-06-20 1985-07-16 E.R. Squibb & Sons, Inc. 17-(substituted thio)-17-(substituted dithio)androstenes
NO163899C (en) * 1984-07-25 1990-08-08 Hovione Int Ltd PROCEDURE FOR THE PREPARATION OF DIISOPROPYLETERS SOLVATES OF BECLOMETASON-17,21-DIPROPIONATE.
RU2028083C1 (en) * 1987-07-10 1995-02-09 Андрюкин Алексей Алексеевич Method of treatment of steroid-dependent bronchial asthma
US5116829A (en) * 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
DE69231991T2 (en) * 1991-06-10 2002-04-04 Schering Corp Chlorofluorocarbon free aerosol formulations
ES2158911T5 (en) * 1991-06-10 2009-12-09 Schering Corporation FORMULATIONS IN AEROSOL WITHOUT CHLOROFLUOROCARBONOS.
CA2078804C (en) * 1991-10-01 2003-02-25 Takehiko Suzuki Manufacture and use of novel glycosides of catechol estrogens
IL108167A0 (en) * 1992-12-24 1994-04-12 Rhone Poulenc Rorer Ltd Steroids, their preparation and pharmaceutical compositions containing them
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
PE44995A1 (en) * 1994-01-27 1995-12-18 Schering Corp MOMETASONE FUROATE FOR THE TREATMENT OF LUNG DISEASES AND RESPIRATORY TRACT
JPH08165242A (en) * 1994-12-09 1996-06-25 Kunio Yagi Anti-artroteriosclerotic agent

Also Published As

Publication number Publication date
CN1245982C (en) 2006-03-22
ATE281170T1 (en) 2004-11-15
US5962445A (en) 1999-10-05
EP0923376B1 (en) 2004-11-03
CA2253943C (en) 2009-09-29
WO1997042958A1 (en) 1997-11-20
EP0923376A1 (en) 1999-06-23
CN1218401A (en) 1999-06-02
EP0923376A4 (en) 2001-09-26
DE69731473T2 (en) 2005-10-27
US6200966B1 (en) 2001-03-13
JP2000507923A (en) 2000-06-27
JP4228116B2 (en) 2009-02-25
DE69731473D1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
CA2253943A1 (en) Treatment of asthma and airway diseases
MY128337A (en) New combination of steroids
HK1035145A1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
ES2133130A1 (en) Novel formulation
AU6392496A (en) The combination of topical nasal antihistamines and topical nasal steroids
AU1758995A (en) Vaccine containing parainfluenza viruses for the prevention of respiratory and reproductive diseases of the pig
AU3218197A (en) Natural progesterone for the treatment of side effects of progestins and progesterone analogues
WO2002083113A3 (en) Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
ZA958047B (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension and for hormone replacement therapy
AU9336098A (en) The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds
AU2469999A (en) Nasal dilator that does not extend over the bridge of the nose
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
PT1073416E (en) Use of inhaled no as anti-inflammatory agent
CA2199844A1 (en) Compositions for the treatment of skin disorders
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
IL125446A0 (en) Pharmaceutical composition for the treatment of asthma allergy and inflammation
AU6471500A (en) Aqueous nasal formulation
AU2112995A (en) Use of estrone derivatives as steroid sulphatase inhibitors
AU6367496A (en) New hormonal medicaments and their use for the correction of oestrogenic deficiencies
AU1289300A (en) Diagnosis of gastric and lung disorders
AU2548795A (en) Antithrombin agents in treatment of asthma
IL105061A (en) Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof
EP1101493A3 (en) New combination of formoterol and budesonide
AU6690898A (en) Composition for the treatment of exercise induced pulmonary hemorrhage and inhaler for administering said composition

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150511

MKLA Lapsed

Effective date: 20150511